AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
146 hedge funds and large institutions have $1.09B invested in Aimmune Therapeutics in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 55 increasing their positions, 27 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
6% more capital invested
Capital invested by funds: $1.02B → $1.09B (+$65.2M)
20% less call options, than puts
Call options by funds: $13M | Put options by funds: $16.2M
Holders
146
Holding in Top 10
5
Calls
$13M
Puts
$16.2M
Top Buyers
| 1 | +$22.8M | |
| 2 | +$17.7M | |
| 3 | +$13.1M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$8.75M |
Top Sellers
| 1 | -$21.6M | |
| 2 | -$20.1M | |
| 3 | -$15.7M | |
| 4 |
Franklin Resources
San Mateo,
California
|
-$8.23M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$7.47M |